PRT-001 / Protai Bio - LARVOL DELTA

Discovery of KAT6A degrader enabled by structural proteomics and AI (AACR 2026) - "KAT6 PROTAC can target both its enzymatic and scaffold functionalities, potentially leading to improved efficacy...The resulting PAI-PROTAC demonstrates efficient KAT6A degradation and growth inhibition in ER+ breast cancer cell lines, with high selectivity over KAT6B and over other KAT enzymes, as well as no degradation activity in CRBN neosubstrates. Altogether, these results illustrate how proteomics-aware-AI enables rational PROTAC design, leading to discovery of a potent and selective KAT6A degrader."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CRBN • ER • KAT6A • KAT6B